The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.
Dermatology Clinical Trials Unit
Phone: (314) 273-3897
Email: DermTrials@email.wustl.edu
EPIC: WU IM DERM CLINICAL TRIALS POOL
Currently Enrolling Trials
ATOPIC DERMATITIS
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up)
ClinicalTrials.gov Identifier: NCT06461897
CUTANEOUS T-CELL LYMPHOMA
A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Topical HyBryte (Hypericin Sodium) and Visible-Light Activation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
ClinicalTrials.gov Identifier: NCT06470451
HIDRADENITIS SUPPURATIVA
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib (oral JAK-i) in Adult and Adolescent Subjects (Ages 12 and older) with Moderate to Severe Hidradenitis Suppurativa Who Have Failed an Approved Biologic Therapy
ClinicalTrials.gov Identifier: NCT05889182
A Phase 3, Double-blind, Randomized, Vehicle-controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants (Ages 12 and older) with Hidradenitis Suppurativa (HS)
Clinical Trials.gov Identifier: NCT06959225
PRURIGO NODULARIS
(STOP-PN1) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis